| HOME >> BIOLOGY >> TECHNOLOGY |
AMSTERDAM, November 30 /PRNewswire-FirstCall/ -- Elsevier, the world's leading publisher of scientific, medical and technical products and services, today announced a major re-launch of Embase, its comprehensive biomedical database which holds over 20 million indexed records from more than 7,000 active, peer reviewed journals.
Embase has long played a key role in the advancement of new biomedical and pharmaceutical insights. Now, new developments and updates include:
- Enabling all biomedical researchers to use Embase --
extending its "usability" from information specialists to also include
all biomedical and pharmaceutical scientists, and clinical and
regulatory professionals.
- New retrieval tools that further drive discovery, including
quick and easy refining of search results and the display of indexed
drug-drug and drug-disease relations.
- Improved comprehensiveness through the addition of indexed
articles-in-press and conference abstracts.
- To signify the enhanced focus on biomedical answers, the
product has a new, fresh look and feel to it.
Thomas Gutjahr, Head of the Knowledge Center at Actelion Pharmaceuticals Ltd., comments: "I'm very impressed by all the new improvements which I believe will greatly help with pin-pointing certain searches, e.g. drug-drug interactions or drug-disease searches."
Embase supports researchers with key tasks such as tracking of drug adverse events, comparing drug therapies, and Evidence Based Medicine research. It provides researchers with deep insights and understanding from the world's life sciences information, enabling effective discoveries towards medical discovery and treatment.
ABOUT ELSEVIER
Elsevier is a world-leading publisher of scientific, technical and
medical information products and services. The company works in p
'/>"/>
| SOURCE Elsevier Copyright©2009 PR Newswire. All rights reserved |